At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10,398 enrolled
Drug / intervention
Pentoxifylline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol
In Brief
An observational study evaluating Pentoxifylline and Cilostazol for Peripheral Artery Disease. Completed, enrolled 10,398 participants across 1 site.
Detailed Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Artery Disease
CountriesUnited States
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartNov 2022
First PostedDec 2022
Primary CompletionJul 2023
Study CompletionDec 2023
TodayJul 2026
First PostedDec 2, 2022
Enrollment StartNov 1, 2022
Primary CompletionJul 7, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.6 years ago
Interventions
Pentoxifyllinedrug
Pentoxifylline claim is used as the exposure group.
Cilostazoldrug
Cilostazol claim is used as the reference group.